Alzheimer’s disease, a progressive neurodegenerative disorder that affects millions worldwide, has a long preclinical stage. It potentially begins decades before clinical symptoms become apparent.

But as our new research suggests, blood biomarkers in combination with self-reported memory concerns could offer an early clue to how...